140 related articles for article (PubMed ID: 28422428)
1. Identification of Transthyretin Fibril Formation Inhibitors Using Structure-Based Virtual Screening.
Ortore G; Martinelli A
ChemMedChem; 2017 Aug; 12(16):1327-1334. PubMed ID: 28422428
[TBL] [Abstract][Full Text] [Related]
2. Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods.
Simões CJ; Mukherjee T; Brito RM; Jackson RM
J Chem Inf Model; 2010 Oct; 50(10):1806-20. PubMed ID: 20883031
[TBL] [Abstract][Full Text] [Related]
3. Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds.
Ortore G; Orlandini E; Braca A; Ciccone L; Rossello A; Martinelli A; Nencetti S
ChemMedChem; 2016 Aug; 11(16):1865-74. PubMed ID: 27159149
[TBL] [Abstract][Full Text] [Related]
4. Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.
Grimm FA; Lehmler HJ; He X; Robertson LW; Duffel MW
Chem Biol Interact; 2015 Feb; 228():1-8. PubMed ID: 25595224
[TBL] [Abstract][Full Text] [Related]
5. X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors.
Ciccone L; Nencetti S; Rossello A; Tepshi L; Stura EA; Orlandini E
J Enzyme Inhib Med Chem; 2016 Oct; 31(5):824-33. PubMed ID: 26235916
[TBL] [Abstract][Full Text] [Related]
6. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
Tomar D; Khan T; Singh RR; Mishra S; Gupta S; Surolia A; Salunke DM
PLoS One; 2012; 7(9):e43522. PubMed ID: 22973437
[TBL] [Abstract][Full Text] [Related]
7. Structural evidence for asymmetric ligand binding to transthyretin.
Cianci M; Folli C; Zonta F; Florio P; Berni R; Zanotti G
Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1582-92. PubMed ID: 26249340
[TBL] [Abstract][Full Text] [Related]
8. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.
Guo X; Liu Z; Zheng Y; Li Y; Li L; Liu H; Chen Z; Wu L
Drug Des Devel Ther; 2020; 14():1057-1081. PubMed ID: 32210536
[TBL] [Abstract][Full Text] [Related]
9. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
Palaninathan SK
Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
[TBL] [Abstract][Full Text] [Related]
10. Conserved water mediated H-bonding dynamics of Ser117 and Thr119 residues in human transthyretin-thyroxin complexation: inhibitor modeling study through docking and molecular dynamics simulation.
Banerjee A; Bairagya HR; Mukhopadhyay BP; Nandi TK; Mishra DK
J Mol Graph Model; 2013 Jul; 44():70-80. PubMed ID: 23732306
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors.
Li W; Duan X; Yan H; Xin H
Org Biomol Chem; 2013 Jul; 11(27):4546-50. PubMed ID: 23733168
[TBL] [Abstract][Full Text] [Related]
12. Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
Kim B; Park H; Lee SK; Park SJ; Koo TS; Kang NS; Hong KB; Choi S
Eur J Med Chem; 2016 Nov; 123():777-787. PubMed ID: 27541261
[TBL] [Abstract][Full Text] [Related]
13. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
14. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors.
Morais-de-Sá E; Pereira PJ; Saraiva MJ; Damas AM
J Biol Chem; 2004 Dec; 279(51):53483-90. PubMed ID: 15469931
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
16. Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
Ciccone L; Nencetti S; Tonali N; Fruchart-Gaillard C; Shepard W; Nuti E; Camodeca C; Rossello A; Orlandini E
Bioorg Med Chem; 2020 Sep; 28(18):115673. PubMed ID: 32828431
[TBL] [Abstract][Full Text] [Related]
17. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
18. TTR fibril formation inhibitors: is there a SAR?
Nencetti S; Orlandini E
Curr Med Chem; 2012; 19(15):2356-79. PubMed ID: 22471984
[TBL] [Abstract][Full Text] [Related]
19. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation.
Ferreira N; Saraiva MJ; Almeida MR
FEBS Lett; 2011 Aug; 585(15):2424-30. PubMed ID: 21740906
[TBL] [Abstract][Full Text] [Related]
20. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.
Palaninathan SK; Mohamedmohaideen NN; Orlandini E; Ortore G; Nencetti S; Lapucci A; Rossello A; Freundlich JS; Sacchettini JC
PLoS One; 2009 Jul; 4(7):e6290. PubMed ID: 19621084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
